Posted by Michael Wonder on 04 Apr 2025
Aldeyra Therapeutics receives complete response letter from the US FDA for the reproxalap new drug application for the treatment of signs and symptoms of dry eye disease
3 April 2025 - Pending positive results and discussions with the FDA, new drug application resubmission expected mid 2025.
Aldeyra Therapeutics today announced receipt of a complete response letter from the US FDA for the resubmission of the new drug application of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.
